GI Navigator launches in Australia and the UK
Microba Life Sciences (ASX: MAP) has announced the commercial launch of GI Navigator, a new clinical gut test designed to help healthcare practitioners resolve complex gastrointestinal (GI) symptoms. The test is available from today in Australia and the United Kingdom.
Early demand figures were released alongside the launch:
- Over 150 tests ordered by leading clinicians in the beta program ahead of launch
- Over 400 practitioners on the GI Navigator waitlist
- More than 150 of those waitlisted practitioners had not previously ordered a Microba test
The pre-launch figures suggest the product is reaching practitioners beyond Microba’s existing customers, although the announcement does not disclose revenue.
A/Prof Lutz Krause, Chief Scientific Officer
“The launch of GI Navigator is a major milestone for Microba… The response from practitioners ahead of launch has been very encouraging, with over 150 tests already ordered and more than 400 practitioners on the waitlist…”
When big ASX news breaks, our subscribers know first
What GI Navigator does for practitioners
One sample, one report
GI Navigator is designed for patients with complex or persistent GI symptoms. It uses one stool sample collected at home and a 15-minute online questionnaire completed by the patient, interpreted by Microba’s proprietary Clinical Logic Engine. Microba describes it as a “world-first full microbiome and gut test”.
According to the company, the test delivers:
- Superior coverage: full microbiome mapping, patient presentation assessment, gut physiology and pathogen screening in one test.
- Clear, accessible interpretations: results practitioners can readily understand and explain to patients.
- Personalised, prioritised actions: suggested next steps across diet, supplements, exercise and more.
- Practice support features: tools including a web portal, in-clinic collaboration features, flexible payment terms, live interactive report sharing, access to in-house clinical support and 24-hour customer support.
Results are typically available within two to four weeks from receipt at Microba’s laboratory.
Where it sits in the portfolio
GI Navigator focuses on complex or persistent GI symptoms, while Microbiome Explorer is used to evaluate a broader range of systemic health issues. Practitioners can now choose the test that best suits the patient in front of them.
Microbiome Explorer has also been upgraded to a clinical-grade platform under the SYNLAB agreement, extending the portfolio’s distribution across Europe and Latin America beyond the Australian and UK launch markets.
Microba notes that GI Navigator is a clinical decision support tool. Its interpretations are intended to inform, not replace, clinical judgement.
Why gut testing matters: the 82 million patient opportunity
Routine gut tests generally look for a single cause, such as an infection or inflammation. Microbiome testing (analysis of the bacteria and other microbes living in the gut) gives a broader view, but interpreting results has required time and specialist knowledge.
According to Microba, that requirement has limited uptake among time-poor medical doctors, and GI Navigator has been developed to address this.
The announcement cites the following data:
- An estimated 82 million patients present each year with lower GI symptoms across the US, Germany, Italy, Spain, France, the United Kingdom and Australia
- An estimated 50% of these patients are left without a resolution under the current standard of care
- Around 40% of people live with an ongoing functional gut disorder
The 82 million figure comes from an assessment completed with Boston-based MedTech consultancy Veranex Inc., which analysed billing and claims data. It is an estimate of the addressable patient population, not a Microba sales forecast.
For investors, the announcement describes medical doctors, including GPs and gastroenterologists, as a significant next segment of the healthcare practitioner market for Microba’s tests.
Commercial rollout and what to watch
GI Navigator is ordered through the Microba practitioner portal. The introductory price may be paid by either the patient or the practitioner.
| Market | Introductory price | Existing practitioner network (at 30 June 2026) |
|---|---|---|
| Australia | $549 | Over 900 |
| United Kingdom | £399 | Over 300 |
Microba’s existing network of clinicians can order the test immediately. The launch is supported by:
- Email and social media campaigns reaching practitioners in Microba’s network
- Digital and print advertising
- Practitioner events in Australia and the UK during October and November
Testing is processed through Microba’s existing laboratory and digital platform. The announcement does not disclose any margin or cost impact.
Microba’s cashflow breakeven target for the end of CY2027 provides the wider financial context for the launch, with 11 consecutive quarters of testing sales growth already behind the company.
Microba will report GI Navigator sales in its quarterly activities reports, starting with the December 2026 quarter. No revenue guidance or sales forecasts were provided, so those reports are likely to be the first source of commercial data for investors to track.
A demonstration video and further information are available on the GI Navigator page of the Microba practitioner site at www.microba.com/practitioners/products/gi-navigator.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors receiving FREE breaking ASX news from Big News Blast within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button to get healthcare and biotech announcements in your inbox the moment they break, so you stay ahead of the market.